Gilteritinib outperformed salvage chemotherapy in relapsed/refractory (R/R) settings (Perl et al., 2019; Smith et al., 2022), while quizartinib, integrated across induction, consolidation, and continuation, conferred an OS benefit in FLT3-ITD AML (Erba et al., 2023). This evidence concerns the gene FLT3 and acute myeloid leukemia.